IV Insulin (Apidra) For Quick Glycemic Control
The FDA has approved rapid-acting insulin glulisine (rDNA origin) injection (Apidra, Sanofi-Aventis) for intravenous (IV) administration in adults with type-1 and type-2 diabetes.
Apidra was approved in April 2004 for treating diabetes mellitus and controlling hyperglycemia. It can also be given subcutaneously in vial form, by insulin pen, or by an external insulin infusion pump.
Apidra can be taken within 15 minutes before or within 20 minutes after starting a meal. In clinical studies, the drug maintained its rapid onset of action and absorption in both lean and obese patients.
